GH Research (NASDAQ:GHRS) Trading Up 0.6% – Should You Buy?

Shares of GH Research PLC (NASDAQ:GHRS) shot up 0.6% during mid-day trading on Tuesday . The stock traded as high as $8.10 and last traded at $8.05. 13,641 shares traded hands during trading, a decline of 83% from the average session volume of 79,417 shares. The stock had previously closed at $8.00.

Wall Street Analyst Weigh In

Several research firms recently commented on GHRS. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.

GH Research Trading Up 8.6 %

The firm’s 50 day simple moving average is $7.85 and its 200-day simple moving average is $10.47. The stock has a market capitalization of $453.70 million, a price-to-earnings ratio of -13.01 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, equities research analysts predict that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the quarter. GH Research makes up about 16.7% of Lynx1 Capital Management LP’s portfolio, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).